<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medical management of acute uterine bleeding in hemodynamically stable patients: Choice of therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medical management of acute uterine bleeding in hemodynamically stable patients: Choice of therapy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Medical management of acute uterine bleeding in hemodynamically stable patients: Choice of therapy</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Choice of therapy</td> <td class="subtitle1">Drug</td> <td class="subtitle1">Dose and duration (oral)</td> <td class="subtitle1">Comments</td> </tr> <tr> <td><strong>Preferred for most patients: High-dose combined oral contraceptives</strong><sup>*</sup></td> <td> <p>Combined estrogen-progestin oral contraceptives containing 35 mcg ethinyl estradiol; combinations with 30 or 50 mcg of ethinyl estradiol have also been used.</p> Use monophasic combinations only.</td> <td>Multiple regimens have been described; tapering regimen examples for tablets containing 30, 35, or 50 mcg of ethinyl estradiol include: <ul class="decimal_heading"> <li>5 tablets on day 1, then 4 tablets on day 2, then 3 tablets on day 3, then 2 tablets on day 4, then 1 tablet daily<sup>¶</sup>, <strong>or</strong></li> <li>1 tablet 3 times per day for 7 days, then taper as tolerated to maintain control of bleeding, <strong>or</strong></li> <li>1 tablet every 6 to 8 hours until cessation of bleeding (24 to 48 hours), then taper as tolerated to maintain control of bleeding.</li> </ul> </td> <td> <p>Option for patients without contraindications to estrogen therapy.</p> <p>Bleeding typically subsides within 48 hours.</p> <p>To improve tolerability, an antiemetic may be prescribed.</p> <p>Omit inactive (placebo) tablets.</p> After acute bleeding resolves, begin maintenance treatment (eg, monthly or extended cycle COC regimen).</td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Alternative for patients who may benefit from a quicker onset of action: High-dose oral estrogen</strong></td> <td>Conjugated equine estrogen</td> <td> <p>2.5 mg orally every 6 hours.</p> When bleeding subsides or is minimal, the dose may be decreased to 2.5 mg orally twice daily.</td> <td> <p>Option for patients without contraindications to estrogen therapy.</p> <p>Bleeding typically subsides within 10 hours of first dose.</p> Treatment is typically continued for not more than 21 to 25 days. After discontinuation, a progestin is then prescribed to induce a withdrawal bleed (eg, medroxyprogesterone acetate 10 mg once daily for 10 days).</td> </tr> <tr> <td rowspan="3"><strong>Alternative for patients in whom the suspected etiology of acute bleeding is from anovulation: Oral progestins</strong></td> <td>Medroxyprogesterone acetate, <strong>or</strong></td> <td>10 to 20 mg 3 times daily for 5 to 10 days.</td> <td rowspan="3"> <p>Patients with anemia may benefit from longer durations (eg, a 1- to 2-month treatment period in conjunction with iron allows an increase in hemoglobin/hematocrit); however, long-term tolerability is limited by adverse effects (eg, acne, mood changes, weight gain, headache, lipid abnormalities).</p> After resolution of acute bleeding, transition to maintenance dosing or another progestin (eg, levonorgestrel IUD). Refer to related UpToDate content.</td> </tr> <tr> <td>Megestrol acetate, <strong>or</strong></td> <td>20 to 60 mg 2 times daily for 5 to 10 days.<sup>Δ</sup></td> </tr> <tr> <td>Norethindrone</td> <td>5 mg 1 to 4 times daily for 5 to 10 days.</td> </tr> <tr class="highlight_lght_gray_text"> <td rowspan="2"><strong>Treatments less commonly used</strong></td> <td>Tranexamic acid, <strong>or</strong></td> <td>1.3 g 3 times daily.<sup>◊</sup></td> <td> <p>Subsequent-line therapy for patients not at high risk of thrombosis.</p> Typically acts within 2 to 3 hours of administration.</td> </tr> <tr class="highlight_lght_gray_text"> <td>GnRH analogs</td> <td>Discussed in related UpToDate content.</td> <td>Use of these agents may be considered if the above methods have failed or are contraindicated.</td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>Hemodynamically <strong>unstable</strong> patients are typically managed with uterine curettage or high-dose intravenous estrogen. This is discussed in detail separately.</p>
Hemodynamically <strong>stable</strong> patients who prefer to avoid hormonal therapies or in whom medical therapy is contraindicated or unsuccessful can be managed surgically (eg, endometrial ablation, uterine curettage, uterine artery embolization). This is discussed in related UpToDate content.</div><div class="graphic_footnotes"><p>COC: combined oral contraceptives; GnRH: gonadotropin-releasing hormone; IUD: intrauterine device.</p>
<p>* A table of oral contraceptives is available separately in UpToDate.</p>
<p>¶ Daily dose may be taken at one time or tablets may be separated by several hours to improve tolerability. For patients with moderate bleeding, may start with 3 tablets daily.</p>
<p>Δ May cause weight gain (acts as an appetite stimulant), particularly at higher doses. Dose selection is based on shared decision-making and tolerance of side effects.</p>
◊ Available as 650 mg tablets in the United States. Dosing in Canada, Europe, and elsewhere may vary.</div><div class="graphic_reference">Information from:
<ol>
<li>Munro MG, Mainor N, Basu R, et al. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol 2006; 108:924.</li>
<li>James AH, Kouides PA, Abdul-Kadir R, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol 2011; 158:124.</li>
<li>Shwayder JM. Pathophysiology of abnormal uterine bleeding. Obstet Gynecol Clin North Am 2000; 27:219.</li>
<li>Bayer SR, DeCherney AH. Clinical manifestations and treatment of dysfunctional uterine bleeding. JAMA 1993; 269:1823.</li>
<li>Aksu F, Madazli R, Budak E, et al. High-dose medroxyprogesterone acetate for the treatment of dysfunctional uterine bleeding in 24 adolescents. Aust N Z J Obstet Gynaecol 1997; 37:228.</li>
<li>Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995; 102:401.</li>
</ol></div><div id="graphicVersion">Graphic 142886 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
